CrowdStrike heads into mid-July with short interest consolidating at elevated levels, a wave of analyst target resets washing through the Street, and the stock giving back roughly 6% on the week — a setup worth watching closely ahead of the August 25 earnings date.
The short interest picture has clarified since the prior notes flagged data anomalies around the July 2 spike. The current reading of 28.3 million shares — 11.3% of the free float — is consistent with the July 10 level of 28.6 million shares and represents a genuine, sustained build. That is roughly four times where short interest sat through most of June (around 7.3–7.6 million shares), confirming the acceleration flagged in the July 8 note was real rather than artefact-driven. The borrow market offers no squeeze pressure whatsoever: availability is essentially uncapped at present levels, cost to borrow has eased to 0.33% from its brief spike above 0.98% last week, and the ORTEX short score of 32.6 — though up from the mid-27s earlier this month — remains comfortably in moderate territory. Options have also normalised completely. The put/call ratio is running near 0.99, well below its 20-day average of 1.35 and close to its 52-week low of 0.82. The extreme defensiveness of the July 2 session (PCR 8.11) has been entirely unwound; if anything, options traders now lean mildly bullish relative to recent history. The contrast is notable: a meaningful short build, yet no sign of borrow stress and no options hedging to match.
The analyst community spent the week absorbing what appears to be a post-split target repricing. Several firms — Needham, Benchmark, Stifel, Barclays, and Morgan Stanley — all substantially lowered headline price targets this week, with moves from prior targets in the $675–$790 range down to $169–$235. The prior targets look inconsistent with the current $187.91 share price and almost certainly reflect a stock split that was not yet reflected in those older figures; the new targets sit in a more coherent $169–$235 range. The direction of travel is worth noting: Morgan Stanley's Keith Weiss maintained Overweight but kept his target at $172, below the current price. UBS moved the other way, raising its target to $235 from $198 — the sole upgrade in target terms this week. The consensus mean price target of $184.31 sits fractionally below where the stock is trading, suggesting the Street's aggregate view has caught up with price rather than offering a meaningful premium. Factor scores back up a mixed picture: forward EPS growth ranks in the 94th percentile across the universe, a genuine bull case, but the short-score rank of 59 and days-to-cover rank of 69 reflect the building short position. Valuation remains stretched — a PE of 123x and EV/EBITDA of 84.7x leave little room for disappointment.
Institutional ownership is deep and broadly stable. BlackRock holds 8.4% of shares, and State Street added a substantial 37.8 million shares to reach 4.4% as of June 30 — a notable accumulation. On the insider side, founder and CEO George Kurtz sold approximately $1.6 million in shares on July 10 across a series of transactions at prices between $187 and $197. The trade significance scores are low, consistent with a pre-scheduled plan, but the sales came as the stock was near its post-split highs and add a mild headwind to sentiment.
Among close peers, the week's selling pressure was not unique to CRWD. PANW fell 7.6% and TENB dropped 5.1%, while DDOG bucked the trend with a 1.9% gain. The broad cybersecurity softness makes it harder to read the CRWD move as company-specific, though the concurrent short build suggests at least some incremental conviction among bears.
With Q1 FY2027 results scheduled for August 25 — and the most recent print in June delivering a 6.5% next-day drop and a 15.8% five-day decline — the next few weeks centre on whether the short build reflects genuine fundamental concern or simply tactical positioning ahead of a volatile earnings event.
See the live data behind this article on ORTEX.
Open CRWD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
